Get startedLog in
    Picture of Neoimmunetech logo

    950220 — Neoimmunetech Cashflow Statement

    0.000.00%
    kr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Neoimmunetech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-45.9-46.8-40.9-30-22.4
    Depreciation
    Amortisation
    Non-Cash Items9.436.092.861.083.96
    Unusual Items
    Purchased R&D
    Other Non-Cash Items
    Changes in Working Capital6.265-3.03-2.43-0.977
    Change in Accounts Receivable
    Change in Prepaid Expenses
    Change in Accounts Payable
    Change in Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-28.6-33.5-38.6-28.6-17.6
    Capital Expenditures-2.29-1.95-0.614-1.14-5.06
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-0.944-0.5322.23-7.35-5.49
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-3.23-2.491.62-8.48-10.5
    Financing Cash Flow Items————-0.728
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities97-0.5-0.8818.2232.9
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash64.7-38.9-37.9-30.13.82